⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer

Official Title: Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer

Study ID: NCT00604994

Interventions

Study Description

Brief Summary: This project will conduct a prospective, longitudinal, observational cohort study to assess the onset and incidence of lymphoedema, as well as investigate factors associated with its development among women newly diagnosed with gynaecological cancers in 2008 to 2011.

Detailed Description: Pathological swelling of the lower limbs (lymphoedema) is widely accepted to be a common consequence of treatment for gynaecological cancer. It is both a serious and debilitating complication, associated with significant morbidity, which impacts physically and emotionally on otherwise healthy women. Lymphoedema can also affect patients' ability to earn an income, especially if their work requires prolonged periods of standing or walking. The causes of lymphoedema are largely unknown with clinical data scarce regarding its onset time and incidence after gynaecological cancer treatment. The following hypotheses will be tested to address the aims of the project: 1. At least 20% of patients will develop lower-limb lymphoedema following gynaecological cancer treatment. 2. Patient's age, as well as their body mass index (BMI), area of residence, degree of physical exercise, type of disease (uterine, cervical, ovarian, vulval/vaginal cancer; benign disease), mode of treatment (extent of lymph node dissection, radiotherapy, chemoradiation) and delay in wound healing are independent risk factors for lower-limb lymphoedema. 3. Patients who develop lymphoedema after gynaecological cancer treatment, will experience increased pain, lower quality of life (including worse body-image), and decreased sexual \& financial well-being, compared to those who do not develop lymphoedema. 4. There will be at least 10% difference in the incidence of lower-limb lymphoedema between patients treated for gynaecological cancer compared to benign diseases.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

The Wesley Hospital, Auchenflower, Queensland, Australia

Greenslopes Private Hospital, Greenslopes, Queensland, Australia

Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

Mater Health Services, South Brisbane, Queensland, Australia

Royal Women's Hospital, Carlton, Victoria, Australia

Contact Details

Name: Andreas Obermair, MD FRANZCOG CGO

Affiliation: Queensland Centre for Gynaecological Cancer

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: